» Articles » PMID: 23512691

Long-term Treatment of Hypogonadal Men with Testosterone Produces Substantial and Sustained Weight Loss

Overview
Date 2013 Mar 21
PMID 23512691
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study analyzed the effects of normalization of serum testosterone (T) levels on anthropometric parameters in hypogonadal men.

Design And Methods: Open-label, single-center, cumulative, prospective registry study of 255 men (aged 33-69 years, mean 58.02 ± 6.30 years), with T levels below 12.13 nmol/L (mean: 9.93±1.38). 215 men for at least 2 years, 182 for 3 years, 148 for 4, and 116 for at least 5 years were studied. They received parenteral T undecanoate 1,000 mg/12 weeks after an initial interval of 6 weeks.

Results: Body weight (BW) decreased from 106.22 ± 16.93 kg to 90.07 ± 9.51 kg. Waist circumference (WC) reduced from 107.24 ± 9.14 cm to 98.46 ± 7.39 cm. BMI (m/kg(2) ) declined from 33.9 ± 5.51 m/kg(2) to 29.13 ± 3.09 m/kg(2) . All parameters examined were statistically significant with P < 0.0001 versus baseline and versus the previous year over 5 years indicating a continuous weight loss over the full observation period. The mean per cent weight loss after 1 year was 4.16 ± 0.31%, after 2 years 7.54 ± 0.32%, after 3 years 9.23 ± 0.33%, after 4 years 11.42 ± 0.35% and after 5 years 13.57 ± 0.37%.

Conclusions: In an uncontrolled, observational cohort, normalizing serum T to normal physiological levels produced consistent loss of BW, WC, and BMI. These improvements were progressive over the full 5 years of the study.

Citing Articles

Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction.

Chen B, Tsai P, Jiann B Sex Med. 2025; 12(6):qfae089.

PMID: 39801930 PMC: 11723798. DOI: 10.1093/sexmed/qfae089.


Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review.

Mlynarz N, Miedziaszczyk M, Wieckowska B, Szalek E, Lacka K Int J Mol Sci. 2024; 25(22).

PMID: 39596286 PMC: 11594927. DOI: 10.3390/ijms252212221.


Management of male obesity-related secondary hypogonadism: A clinical update.

Shenoy M, Mondal S, Fernandez C, Pappachan J World J Exp Med. 2024; 14(2):93689.

PMID: 38948417 PMC: 11212738. DOI: 10.5493/wjem.v14.i2.93689.


The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice.

Hackett G, Kirby M, Rees R, Jones T, Muneer A, Livingston M World J Mens Health. 2023; 41(3):508-537.

PMID: 36876744 PMC: 10307648. DOI: 10.5534/wjmh.221027.


Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.

Yazici D, Eser H, Kiyici S, Sancak S, Sezer H, Uygur M Obes Facts. 2022; 16(2):149-163.

PMID: 36349778 PMC: 10028372. DOI: 10.1159/000526808.